Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months after diagnosis. Numerous targeted agents have been developed and evaluated to improve the survival benefit in patients with PDAC. Unfortunately, most agents have been proven futile mainly owing to the dense stroma and the sophisticated signaling pathways of PDAC. Here, we show the potent effectiveness of Aptamer‐SH2 superbinder‐(Arg)9 conjugate on the treatment of PDAC. In this conjugate, DNA aptamer selected against PDAC cell line confers the function of specifically recognizing and binding to the PDAC cells and activated pancreatic stellate cells (PSCs) in stroma; cell penetrating peptide (Arg)9 facilitates the intracellular delivery of fused proteins; SH2 superbinder conducts the drastic blockade of multiple phosphotyrosines (pY)‐based signaling pathways in tumor cells. METHODS: PDAC‐associated pY were reanalyzed by bioinformatics screen. XQ‐2d and SH2 superbinder‐(Arg)9 were crosslinked with BMH to form XQ‐2d‐SH2 CM‐(Arg)9 conjugate. Immunofluorescence was utilized to assess the potency of the conjugate entering cells. MTT and wound healing assays were performed to evaluate the proliferation or migration of PANC‐1 and BxPC‐3 cells, respectively. Western blot and Pulldown assays revealed that conjugate influenced several pY‐based signaling pathways. Tumor‐bearing mice were used to validate XQ‐2d‐SH2 CM‐(Arg)9, which restrained the growth and metastasis of cancer cells. RESULTS: XQ‐2d‐His‐SH2 CM‐(Arg)9 conjugate restrained proliferation, invasion, and metastasis of PDAC cells with potent efficacy via blocking the activity of several pY‐related signaling cascades. XQ‐2d‐His‐SH2 CM‐(Arg)9 could eliminate the dense stroma of PDAC and then arrive at tumor tissues. CONCLUSIONS: XQ‐2d‐SH2 CM‐(Arg)9 conjugate may efficiently destroy the pancreatic stroma and show potent antitumor efficacy with minimal toxic effect by regulating tumor cell proliferation and metastasis in vitro and in vivo, which makes it to be a promising targeted therapy of PDAC.